S B Haga

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Public perspectives about pharmacogenetic testing and managing ancillary findings
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Genet Test Mol Biomarkers 16:193-7. 2012
  2. pmc Promoting public awareness and engagement in genome sciences
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, 304 Research Drive, Durham, NC 27708, USA
    J Genet Couns 22:508-16. 2013
  3. pmc Public knowledge of and attitudes toward genetics and genetic testing
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Genet Test Mol Biomarkers 17:327-35. 2013
  4. pmc Primary care physicians' knowledge of and experience with pharmacogenetic testing
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Clin Genet 82:388-94. 2012
  5. pmc Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, 304 Research Drive, Durham, NC 27708, USA
    Clin Genet 82:115-20. 2012
  6. pmc Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design
    Alex H Cho
    Center for Personalized Medicine, Duke University, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    BMC Health Serv Res 12:16. 2012
  7. pmc Survey of US public attitudes toward pharmacogenetic testing
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Pharmacogenomics J 12:197-204. 2012
  8. pmc Professional perspectives about pharmacogenetic testing and managing ancillary findings
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Genet Test Mol Biomarkers 16:21-4. 2012
  9. doi request reprint Analysis of educational materials and destruction/opt-out initiatives for storage and use of residual newborn screening samples
    Susanne B Haga
    Institute for Genome Sciences and Policy, Sanford School of Public Policy, Duke University, Durham, North Carolina 27708, USA
    Genet Test Mol Biomarkers 14:587-92. 2010
  10. pmc Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling
    Susanne B Haga
    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    J Gen Intern Med 26:834-40. 2011

Detail Information

Publications33

  1. pmc Public perspectives about pharmacogenetic testing and managing ancillary findings
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Genet Test Mol Biomarkers 16:193-7. 2012
    ..To assess public attitudes toward PGx testing, ancillary disease risk information and related clinical issues, we conducted a series of focus groups...
  2. pmc Promoting public awareness and engagement in genome sciences
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, 304 Research Drive, Durham, NC 27708, USA
    J Genet Couns 22:508-16. 2013
    ..These interactions are critical for maintaining public interest and knowledge about genomic research and applications. ..
  3. pmc Public knowledge of and attitudes toward genetics and genetic testing
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Genet Test Mol Biomarkers 17:327-35. 2013
    ..Variable health literacy and genetic knowledge may pose significant challenges to engaging the general public in personal genomics, specifically with respect to promoting risk comprehension and healthy behaviors...
  4. pmc Primary care physicians' knowledge of and experience with pharmacogenetic testing
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Clin Genet 82:388-94. 2012
    ..Development of effective tools for guiding PCPs in the use of PGx tests should be a high priority...
  5. pmc Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, 304 Research Drive, Durham, NC 27708, USA
    Clin Genet 82:115-20. 2012
    ..At this early stage of PGx testing, the role of geneticists and genetic counselors is unclear. However, their experience may aid in readying PGx testing and informing delivery strategies into clinical practice...
  6. pmc Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design
    Alex H Cho
    Center for Personalized Medicine, Duke University, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    BMC Health Serv Res 12:16. 2012
    ....
  7. pmc Survey of US public attitudes toward pharmacogenetic testing
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Pharmacogenomics J 12:197-204. 2012
    ..Given differences in interest among some groups, providers should clearly discuss the purpose of testing, alternative testing options (if available) and policies to protect patient privacy and confidentiality...
  8. pmc Professional perspectives about pharmacogenetic testing and managing ancillary findings
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Genet Test Mol Biomarkers 16:21-4. 2012
    ..Although many PCPs felt an obligation to disclose information about ancillary disease risk, geneticists did not believe that it was always necessary, noting the complexities of genetic risk results such as incomplete penetrance...
  9. doi request reprint Analysis of educational materials and destruction/opt-out initiatives for storage and use of residual newborn screening samples
    Susanne B Haga
    Institute for Genome Sciences and Policy, Sanford School of Public Policy, Duke University, Durham, North Carolina 27708, USA
    Genet Test Mol Biomarkers 14:587-92. 2010
    ..Development of new policies regarding storage and use of residual NBS samples will require careful consideration of impact on NBS programs, parent and provider educational materials, and respect for parents among other issues...
  10. pmc Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling
    Susanne B Haga
    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    J Gen Intern Med 26:834-40. 2011
    ..There is considerable controversy as to how, and even whether, to incorporate these tests into routine medical care...
  11. pmc Public perspectives regarding data-sharing practices in genomics research
    S B Haga
    Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, NC 27708, USA
    Public Health Genomics 14:319-24. 2011
    ..Re-identification of research participants from sequence data has been shown possible, raising concerns of participants' privacy...
  12. pmc Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Genet Med 13:723-8. 2011
    ..We aimed to assess public interest and concerns about pharmacogenetic tests and ancillary information...
  13. pmc Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results
    Susanne B Haga
    Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, NC 27708, USA
    Genet Med 13:887-90. 2011
    ..We aimed to assess public interest and concerns regarding sharing and storage of pharmacogenetic test results that would facilitate the reuse of pharmacogenetic data across a lifetime of care...
  14. pmc Ethical issues of predictive genetic testing for diabetes
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    J Diabetes Sci Technol 3:781-8. 2009
    ....
  15. doi request reprint Ensuring the safe use of genomic medicine in children
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Clin Pediatr (Phila) 48:703-8. 2009
    ..In particular, the importance of counseling, context, consent, communication, and follow-up in the delivery of genomic risk testing to children and adolescents is highlighted...
  16. ncbi request reprint Adding pharmacogenetics information to drug labels: lessons learned
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Pharmacogenet Genomics 16:847-54. 2006
    ..We review the reasons behind the cautious label changes and discuss some of the lessons that can be learned from these experiences...
  17. ncbi request reprint Prescribing BiDil: is it black and white?
    Susanne B Haga
    Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    J Am Coll Cardiol 48:12-4. 2006
    ..Until more accurate selection criteria are developed to identify patients who are most likely to benefit, both clinicians and the general public will need to consider the unique issues raised by BiDil...
  18. ncbi request reprint Defining the spectrum of genome policy
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, 101 Science Drive, Box 3382, Durham, North Carolina 27708, USA
    Nat Rev Genet 7:966-72. 2006
    ..Here we discuss the spectrum of current issues and debates in genome policy, and how to actively engage all affected stakeholders to promote effective policy making...
  19. ncbi request reprint Teaching resources for genetics
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, 101 Science Drive, Durham, North Carolina 27708, USA
    Nat Rev Genet 7:223-9. 2006
    ..It also describes an integrated approach to teaching genetics, emphasizes the need for continuing teacher education, and encourages the involvement of geneticists and health professionals in providing a teaching resource...
  20. doi request reprint Pharmacogenetic testing: not as simple as it seems
    Susanne B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina27708, USA
    Genet Med 10:391-5. 2008
    ..These issues have implications for informed consent and genetic counseling requirements, and for the role of health professionals...
  21. pmc The potential of a placebo/nocebo effect in pharmacogenetics
    S B Haga
    Duke University, Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Public Health Genomics 12:158-62. 2009
    ..Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome...
  22. pmc Public perspectives on returning genetics and genomics research results
    J O'DANIEL
    Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, NC 27708, USA
    Public Health Genomics 14:346-55. 2011
    ..Public attitudes, particularly those of African-Americans, toward this issue have been understudied...
  23. doi request reprint Factors influencing uptake of pharmacogenetic testing in a diverse patient population
    J O'DANIEL
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Public Health Genomics 13:48-54. 2010
    ..In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history...
  24. pmc Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests
    S B Haga
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    Clin Pharmacol Ther 90:25-7. 2011
    ..However, the level of evidence required to establish clinical utility is often the subject of debate. Determining the most efficient and effective pathway to benefit for a given test is therefore both a practical and an ethical concern...
  25. ncbi request reprint Translating genomic biomarkers into clinically useful diagnostics
    Geoffrey S Ginsburg
    Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Box 3382, Durham, NC 27708, USA
    Expert Rev Mol Diagn 6:179-91. 2006
    ..In addition, efforts will be needed to educate health professionals and the public about genomics-based tools, revise regulatory oversight mechanisms, and ensure privacy safeguards of the information generated from these new tests...
  26. doi request reprint Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals
    Julianne M O'Daniel
    Duke Institute for Genome Sciences and Policy, Duke University, 450 Research Drive, LSRC B342C, Box 91009, Durham, NC 27708, USA
    J Genet Couns 19:387-401. 2010
    ....
  27. doi request reprint Impact of limited population diversity of genome-wide association studies
    Susanne B Haga
    From the Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, North Carolina
    Genet Med 12:81-4. 2010
    ....
  28. doi request reprint Ethical, legal, and social implications of biobanks for genetics research
    Susanne B Haga
    Institute for Genome Sciences and Policy, Center for Genome Ethics, Law, and Policy, Duke University, Durham, NC 27708, USA
    Adv Genet 60:505-44. 2008
    ..K., Sweden, and Estonia, and the proposal for a U.S. population cohort study. The dependence on public participation requires clear and transparent policies developed through inclusive processes...
  29. ncbi request reprint Using pharmacogenetics to improve drug safety and efficacy
    Susanne B Haga
    The Center for the Advancement of Genomics, Rockville, MD, USA
    JAMA 291:2869-71. 2004
  30. ncbi request reprint Genetics. FDA races in wrong direction
    Susanne B Haga
    Center for the Advancement of Genomics, Rockville, MD 20850, USA
    Science 301:466. 2003
    ..We also encourage that increased funding be committed to this important issue...
  31. doi request reprint Letting the genome out of the bottle
    Susanne B Haga
    N Engl J Med 358:2184; author reply 2185. 2008
  32. ncbi request reprint Genomic profiling to promote a healthy lifestyle: not ready for prime time
    Susanne B Haga
    Center for the Advancement of Genomics, 1901 Research Blvd, Sixth Floor, Rockville, Maryland 20850, USA
    Nat Genet 34:347-50. 2003
  33. ncbi request reprint The genetics workforce and workload
    Susanne B Haga
    Genet Med 5:55-7. 2003

Research Grants5

  1. Exploring Attitudes About Data Disclosure and Data-Sharing in Genomics Research
    Susanne Haga; Fiscal Year: 2007
    ..The success of large-scale genomics research initiatives will depend on the support and participation of the public and therefore, their views are critically important to obtain. ..
  2. Pharmacogenetic Testing: Challenges of Clinical Integration
    Susanne Haga; Fiscal Year: 2009
    ..This study will also help inform determinations of whether new health infrastructures for pharmacogenetics are required beyond current systems for successful population-wide integration. ..
  3. Pharmacogenetic Testing: Challenges of Clinical Integration
    Susanne B Haga; Fiscal Year: 2010
    ..This study will also help inform determinations of whether new health infrastructures for pharmacogenetics are required beyond current systems for successful population-wide integration. ..